**Table S1:** Biological safety and biological activity analysis of the clinical-grade cells**$** recognized by the National Institutes for Food and Drug Control (NIFDC)

|  |  |  |
| --- | --- | --- |
|  | **Contents**  | **UCMSC** |
| **Cell Characteristics** | **Cell morphology**  | Adherent growth, fibroblast morphology |
| **Short tandem repeats (STRs)** | Each STR locus has 1-2 alleles  |
| **Cell viability** | 96% |
| **Cell cycle analysis** | G0/G1 41.3% S 31.2% G2/M 20.9%  |
| **Isozyme analysis** | B-type of human origin |
| **Biological safety analysis** | **Species identification and cell cross-contamination between species**  | - |
| **Bacteria and fungi**  | - |
| **Mycoplasma** | - |
| **Human papilloma virus (HPV)** | -  |
| **Human parvovirus B19** | -  |
| **Human immuno deficiency virus I (HIV- I)** | -  |
| **Human immuno deficiency virus II (HIV- II)**  | - |
| **John cunningham virus (JCV)** | - |
| **Epstein-barr virus (EBV)** | - |
| **Human hepatitis C virus (HCV)** | -  |
| **Human hepatitis A virus (HAV)**  | -  |
| **Human cytomegalovirus (HCMV)**  | -  |
| **Human T-lymphotropic virus I (HTLV-I)**  | -  |
| **Human hepatitis B virus (HBV)** | -  |
| **Human herpesvirus 6 (qPCR)**  | -  |
| **Human herpesvirus 7 (qPCR)**  | -  |
| **Human papillomavirus (molecular hybridization)**  | -  |
| **Reverse transcriptase activity** | -  |
| **Bovine virus** | -  |
| **Porcine virus** | - |
| **Bovine serum albumin residuals**  | ＜ 5 ng/mL |
| **Endotoxin level** | ＜0.5 EU/mL |
| **Hemagglutination test of 9- to 11-day-old chick embryo allantoic fluid**  | Negative |
| **Survival rate of 5- to 6-day-old chick embryos**  | ＞90% |
| **Intracerebral and intraperitoneal injections in suckling mice**  | Survival rate＞90% |
| **Intracerebral and intraperitoneal injections in mice**  | Survival rate＞90% |
| **Intraperitoneal injection in guinea pigs**  | Survival rate＞90% |
| **Intracutaneous and subcutaneous injections in rabbits**  | Survival rate＞90% |
|  |

|  |  |
| --- | --- |
|  | [**Cell surface antigen analysis**](http://www.baidu.com/link?url=_pzeZ-1a76OgdTnwavSfJ1FaypDxu2YndCV-i7odQHohYxm75IfMErZh09sEEjKnzoYtN65mJxRFo8GLQy6_Ru6yAPJVzB5lGiy3H1EH6Lyxi85wgTfyPtxDwSA7y8R-yUgIW7ePNfppA89Q5QAuza) |

 | CD73 99.5% CD90 99.1% CD105 97.5%  |
|  |  | CD11b、CD19、CD34、CD 45、HLA-DR≤2% |
| **Biological activity analysis** | **Cell differentiation ability** | Differentiated into adipocytes, osteoblasts and chondrocytes in vitro |
|  | **immunophenotypic properties** | Lymphocyte proliferation inhibition ration 50% |

***$*** This table is translated from NIFDC report numbers, SH20140138 for huc-MSC